Omar Kayaleh is an Oncology physician affiliated with Orlando Health. OpenAlex indexes 28 publications with 602 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1400 S Orange Ave
Orlando, FL 328066100
Telephone
407-648-3800Registry record last updated 9 Nov 2016.
Clinical trials
- Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Sponsor: Orlando Health, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20241 payment
- SANOFI-AVENTIS U.S. LLCProgram year20241 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
31.4%Serotonin-3 Receptor Antagonist15.3%Ondansetron Hcl100%Part D≥79 patientsOpioid Agonist4%Loperamide100%Part D≥22 patients+ 5 more classes in this area
Nervous system
31.3%Phenothiazine17.4%Prochlorperazine Maleate100%Part D≥94 patientsGabapentinoids6.2%Gabapentin100%Part D≥18 patients+ 3 more classes in this area
Cancer & immunology
12%Kinase inhibitor5.6%Imatinib Mesylate70%Lenvima30%Part D<11 patientsIsocitrate Dehydrogenase 1 Inhibitor3.3%Tibsovo100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Karoly Horvath, MD
Orlando Health
Alfredo Voloschin, MD
Orlando Health
Paul Foreman, MD
Orlando Health
Larry Fox, MD
Orlando Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”